ValueScreener

ValueScreener company report

Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ / Healthcare / Biotechnology

Share price

47.25 USD Market dataClose of Oct 15, 2026

Market capitalisation

882.6M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 3, 2026
Ratios computed
Oct 15, 2026
Filed years
16, FY2009 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

93.8% Computed

From the FY2025 filing

Read quality

Valuation

Price to earnings

2.32x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

n/a Computed

FY2025 accounts, priced at the latest close

Why n/a

We do not hold this figure for this company, so there is nothing to show.

Read cash generation

Revenue and net income, as filed

FY2016 Revenue: 20.4M USDFY2016 Net income: -69.2M USDFY2017 Revenue: 4.5M USDFY2017 Net income: -78.0M USDFY2018 Revenue: 44.5M USDFY2018 Net income: -70.5M USDFY2019 Revenue: 59.3M USDFY2019 Net income: -66.9M USDFY2020 Revenue: 108.6M USDFY2020 Net income: -29.7M USDFY2021 Revenue: 149.2M USDFY2021 Net income: -17.9M USDFY2022 Revenue: 120.2M USDFY2022 Net income: -58.6M USDFY2023 Revenue: 116.9M USDFY2023 Net income: -25.1M USDFY2024 Revenue: 179.3M USDFY2024 Net income: 17.5M USDFY2025 Revenue: 294.3M USDFY2025 Net income: 367.0M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
3 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Price to earnings is 2.32x at the close of 2026-10-15 on FY2025 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits below the lowest.

Today, against the Biotechnology industry (53 companies), 2.32x sits at the 10th percentile; the middle half of that group runs from 4.71x to 41.19x.

Is it good

Return on equity was 93.8% in FY2025, in the band labelled "Exceptional, check the leverage" (25.0% and above), on lines anchored on Damodaran's cost-of-capital data, suggesting high returns on shareholders' money, which leverage can also produce.

Today, against the Biotechnology industry (494 companies), 93.8% sits at the 100th percentile; the middle half of that group runs from -146.9% to -28.9%.

Is it safe

Interest coverage was 17.14x in FY2025, in the band labelled "Comfortable" (6.00x and above), on lines anchored on Damodaran's interest-coverage table, suggesting an interest bill operating profit covers many times over.

Year by year against peers
Whether Rigel Pharmaceuticals, Inc.'s gross margin stayed above the median of the Biotechnology industry, year by year. (FY2018 to FY2025, 8 fiscal years of Rigel Pharmaceuticals, Inc. with a comparable figure)
The direction
Which way Rigel Pharmaceuticals, Inc.'s operating margin has moved, and how steadily. (FY2016 to FY2025, 10 filed years of Rigel Pharmaceuticals, Inc.)
What could explain it
What in Rigel Pharmaceuticals, Inc.'s filed statements could explain the movements. (7 readings drawn from the statement lines Rigel Pharmaceuticals, Inc. filed)
What to check next
What to check next on Rigel Pharmaceuticals, Inc., and where in its filings. (5 questions for Rigel Pharmaceuticals, Inc.)
In one paragraph
One paragraph on Rigel Pharmaceuticals, Inc.'s returns, cash, balance sheet and price. (8 of sixteen figures read for Rigel Pharmaceuticals, Inc.)

These are RIGL’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research RIGLPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 3, 2026, accession 0001034842-26-000015.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Rigel Pharmaceuticals, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Return on equity93.8% ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Return on capital employed, pre-tax30.3% ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Return on assets71.5% ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Gross margin93.3% ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Operating margin42.6% ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Net margin124.7% ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
RIGL 124.7%
MNKD 1.7%PHAR 0.8%MDXG 11.6%ETON -5.8%ARDX -15.1%
-15.1%124.7%
Net margin: RIGL against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Rigel Pharmaceuticals, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Current ratio2.42 ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Quick ratio2.30 ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Interest coverage17.14x ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Altman Z-score3.29 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Net debt
Why n/a

The FY2025 balance sheet carries no net debt we could read.

n/a ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Total assets 513.6MTotal liabilities 122.1MShareholders' equity 391.5MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Rigel Pharmaceuticals, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 3, 2026, 0001034842-26-000015).

Rigel Pharmaceuticals, Inc: balance sheet position
Total assets513.6M FiledFY2025 10-K, filed Mar 3, 2026
Total liabilities122.1M FiledFY2025 10-K, filed Mar 3, 2026
Shareholders' equity391.5M FiledFY2025 10-K, filed Mar 3, 2026
Cash155.0M FiledFY2025 10-K, filed Mar 3, 2026
Total debtn/a FiledFY2025 10-K, filed Mar 3, 2026
Net debtn/a
Current ratio2.42
Debt to equityn/a
  • Debt to equity: FY2025: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Rigel Pharmaceuticals, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings2.32x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
P/E on trailing twelve months2.89x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book2.27x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Price to sales3.02x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Enterprise value to EBIT
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Enterprise value to EBITDA
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Price to earnings over growth
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Diluted earnings per share19.48 USD FiledFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Graham number97.66 USD ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015

We publish no fair value or price target of our own. Value RIGL on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Rigel Pharmaceuticals, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Rigel Pharmaceuticals, Inc: valuation
Share price47.25 USD
Market capitalisation882.6M USD
Enterprise value to EBITDAn/a
Graham number97.66 USD
Diluted earnings per share, FY202519.48 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Oct 3, 2016: low 1.31x, median 6.63x, high 116.17x, latest 2.89x. 482 trading days with a meaningful ratio, 2,038 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like Rigel Pharmaceuticals, Inc

  1. MannKind Corporation (MNKD)Market cap 1.03B USD
  2. Pharming Group N.V. (PHAR)Market cap 681.6M USD
  3. MiMedx Group, Inc. (MDXG)Market cap 682.2M USD
  4. Eton Pharmaceuticals, Inc. (ETON)Market cap 1.47B USD
  5. Ardelyx, Inc. (ARDX)Market cap 813.6M USD

Same industry (Biotechnology) and size band (Small, 300M to 2B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

Computed

Rigel Pharmaceuticals, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Free cash flow
Why n/a

The FY2025 filing carries no free cash flow we could read.

n/a ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Free cash flow margin
Why n/a

No free cash flow, and no operating cash flow and capital expenditure pair, is filed for this year.

n/a ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
FY2016 Free cash flow: -76.7M USDFY2016 Net income: -69.2M USDFY2017 Free cash flow: -77.7M USDFY2017 Net income: -78.0M USDFY2018 Free cash flow: -59.9M USDFY2018 Net income: -70.5M USDFY2019 Free cash flow: -43.0M USDFY2019 Net income: -66.9M USDFY2020 Free cash flow: -53.4M USDFY2020 Net income: -29.7M USDFY2021 Free cash flow: 5.3M USDFY2021 Net income: -17.9M USDFY2022 Free cash flow: -74.2M USDFY2022 Net income: -58.6M USDFY2023 Net income: -25.1M USDFY2024 Net income: 17.5M USDFY2025 Net income: 367.0M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Rigel Pharmaceuticals, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
2.32xFY2025Oct 15, 2026
2.27xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports neither free cash flow nor the operating cash flow and capital spending it is built from.
n/aFY2025Mar 3, 2026
n/a The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
n/aFY2025Mar 3, 2026
n/a The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
2.42FY2025Mar 3, 2026
3.02xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a This figure compares a year against the one before it, and we hold one filed year for this company.
3.29FY2025Oct 15, 2026
-0.32FY2025Mar 3, 2026
6/9FY2025Mar 3, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 16 filed fiscal years on record, FY2009 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports Rigel Pharmaceuticals, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

Rigel Pharmaceuticals, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2025294.3M125.5M367.0M19.48n/a42.6%93.8%10-K, Mar 3, 20260001034842-26-000015
FY2024179.3M24.2M17.5M0.99n/a13.5%531.8%10-K, Mar 4, 20250001558370-25-002169
FY2023116.9M-20.5M-25.1M-1.44n/a-17.5%n/m10-K, Mar 5, 20240001558370-24-002475
FY2022120.2M-55.5M-58.6M-3.44-74.2M-46.2%n/m10-K, Mar 7, 20230001558370-23-003035
FY2021149.2M-12.5M-17.9M-1.105.3M-8.4%-59.0%10-K, Mar 1, 20220001558370-22-002551
FY2020108.6M-29.0M-29.7M-1.80-53.4M-26.7%-87.4%10-K, Mar 2, 20210001558370-21-002254
FY201959.3M-69.1M-66.9M-4.00-43.0M-116.5%-124.3%10-K, Feb 27, 20200001558370-20-001624
FY201844.5M-72.7M-70.5M-4.40-59.9M-163.3%-64.1%10-K, Feb 28, 20190001558370-19-001310
FY20174.5M-79.6M-78.0M-6.20-77.7M-1775.6%-77.5%10-K, Mar 6, 20180001558370-18-001555
FY201620.4M-69.7M-69.2M-7.30-76.7M-342.1%-125.8%10-K, Mar 7, 20170001558370-17-001428
  • Revenue, compound annual growth FY2016 to FY2025: 34.5%
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2016 and 2022, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Rigel Pharmaceuticals, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-0.32 ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Piotroski F-score6/9 ComputedFY2025 10-K, filed Mar 3, 2026, 0001034842-26-000015
Named tests met3 of 30 Computed
Beta1.92 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 3 met, 16 not met, 11 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
P/E times P/B (Benjamin Graham); Owner earnings yield; Cheapest quarter on P/E (David Dreman)
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; High F-score, low P/B (Joseph Piotroski); Three forensic scores; Gross margin, turnover (Robert Novy-Marx); Dividends and buybacks; Low beta, profitable; Near the 52-week low; Two thirds of NCAV (Benjamin Graham); High returns, low debt; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Clean books, high ROIC; Cheapest quarter on P/B (David Dreman)
Not measured
Earnings yield and ROIC (Joel Greenblatt); Low PEG, low debt (Peter Lynch); High returns and growth; EV/EBITDA and coverage; High yield, low payout; ROIC at or above WACC; Z-score and coverage (Edward Altman); High return on tangibles; Cash-covered dividend; Cash-flow yield and ROIC; Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(13)
  • Debt to Equity: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • EV/EBIT: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Return on Invested Capital: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • PEG Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • EV/EBITDA: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Free Cash Flow Yield: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Capex To Ocf: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 13 figures could not be read on this company, among them Debt to Equity, EV/EBIT, Return on Invested Capital. Each blank in the table above names the rest, with its reason. 11 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy